These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 33140666)

  • 21. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
    Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
    Luedtke DA; Su Y; Liu S; Edwards H; Wang Y; Lin H; Taub JW; Ge Y
    J Cell Mol Med; 2018 Dec; 22(12):6099-6111. PubMed ID: 30596398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
    Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
    Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the SUMO Pathway Primes All-
    Baik H; Boulanger M; Hosseini M; Kowalczyk J; Zaghdoudi S; Salem T; Sarry JE; Hicheri Y; Cartron G; Piechaczyk M; Bossis G
    Cancer Res; 2018 May; 78(10):2601-2613. PubMed ID: 29487199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML.
    Heuser M; Argiropoulos B; Kuchenbauer F; Yung E; Piper J; Fung S; Schlenk RF; Dohner K; Hinrichsen T; Rudolph C; Schambach A; Baum C; Schlegelberger B; Dohner H; Ganser A; Humphries RK
    Blood; 2007 Sep; 110(5):1639-47. PubMed ID: 17494859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).
    Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J
    Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.
    Verhagen HJ; Smit MA; Rutten A; Denkers F; Poddighe PJ; Merle PA; Ossenkoppele GJ; Smit L
    Blood; 2016 Jan; 127(4):458-63. PubMed ID: 26582376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiation therapy of acute myeloid leukemia: past, present and future.
    Petrie K; Zelent A; Waxman S
    Curr Opin Hematol; 2009 Mar; 16(2):84-91. PubMed ID: 19468269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y
    Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase.
    Wang W; Jiang Z; Wang L; Wang A; Liu J; Chen C; Yu K; Zou F; Wang W; Liu J; Liu Q
    Cancer Lett; 2020 Mar; 473():130-138. PubMed ID: 31904486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular redox state and its relationship to the inhibition of clonal cell growth and the induction of apoptosis during all-trans retinoic acid exposure in acute myeloblastic leukemia cells.
    Mäntymaa P; Guttorm T; Siitonen T; Säily M; Savolainen ER; Levonen AL; Kinnula V; Koistinen P
    Haematologica; 2000 Mar; 85(3):238-45. PubMed ID: 10702810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.
    Wang LN; Tang YL; Zhang YC; Zhang ZH; Liu XJ; Ke ZY; Li Y; Tan HZ; Huang LB; Luo XQ
    Leuk Lymphoma; 2017 Oct; 58(10):2426-2438. PubMed ID: 28276286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.
    Shao X; Liu Y; Li Y; Xian M; Zhou Q; Yang B; Ying M; He Q
    Sci Rep; 2016 Apr; 6():24589. PubMed ID: 27074819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells.
    Tokura Y; Shikami M; Miwa H; Watarai M; Sugamura K; Wakabayashi M; Satoh A; Imamura A; Mihara H; Katoh Y; Kita K; Nitta M
    Leuk Res; 2002 Jan; 26(1):29-36. PubMed ID: 11734301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharicin B stabilizes retinoic acid receptor-α and presents synergistic differentiation induction with ATRA in myeloid leukemic cells.
    Gu ZM; Wu YL; Zhou MY; Liu CX; Xu HZ; Yan H; Zhao Y; Huang Y; Sun HD; Chen GQ
    Blood; 2010 Dec; 116(24):5289-97. PubMed ID: 20739655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An association between mitochondrial function and all-trans retinoic acid-induced apoptosis in acute myeloblastic leukaemia cells.
    Zheng A; Mäntymaa P; Säily M; Siitonen T; Savolainen ER; Koistinen P
    Br J Haematol; 1999 Apr; 105(1):215-24. PubMed ID: 10233386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
    Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
    Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.
    Liu L; Zhang J; Zhang X; Cheng P; Liu L; Huang Q; Liu H; Ren S; Wei P; Wang C; Dou C; Chen L; Liu X; Zhang H; Chen M
    J Mol Med (Berl); 2021 Jan; 99(1):107-118. PubMed ID: 33128580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.
    Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A
    Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.